Company Filing History:
Years Active: 2012
Title: Jun-ichi Shishikura: Innovator in Pharmaceutical Chemistry
Introduction
Jun-ichi Shishikura is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as N-type Ca channel blockers. His innovative work has implications for treating various types of pain and central nervous system disorders.
Latest Patents
Jun-ichi Shishikura holds a patent for a 1-substituted tetrahydroisoquinoline compound. This compound is recognized for its ability to block N-type Ca channels, which is crucial in managing pain. The findings indicate that this tetrahydroisoquinoline compound exhibits antinociceptive and antineuropathic pain actions, as well as an ability to alleviate abdominal pain and improve opioid-induced constipation. The compound can be utilized in pharmaceutical compositions aimed at preventing and treating a range of conditions, including neuropathic pain, migraines, anxiety, depression, and various digestive and urinary system diseases.
Career Highlights
Shishikura is associated with Astellas Pharma GmbH, a leading company in the pharmaceutical industry. His work has been instrumental in advancing the understanding and treatment of pain-related conditions through innovative chemical compounds.
Collaborations
Jun-ichi Shishikura has collaborated with notable colleagues, including Makoto Inoue and Takashi Ogiyama. Their combined expertise has contributed to the successful development of his patented compound.
Conclusion
Jun-ichi Shishikura's contributions to pharmaceutical chemistry highlight the importance of innovation in developing effective treatments for pain and related disorders. His work continues to influence the field and improve patient outcomes.